AIM-listed biopharma Amryt Pharma PLC (LON:AMYT) has signed an exclusive distribution agreement with Saudi Arabian firm Faisal Musaed El Seif Saudi Pharmaceutical Company.
The deal gives El Seif the right to distribute Amryt’s Lojuxta and AP101 drugs in the kingdom.
Lojuxta and AP101
Amryt holds the exclusive marketing rights to Lojuxta last December. The drug treats a rare and life-threatening condition called Homozygous Familial Hypercholesterolemia, which causes abnormally high levels of bad cholesterol.
It is estimated that there are more than 150 patients with HoFH in Saudi Arabia.
There is currently a lot of excitement around AP101 – the other drug covered by the agreement – which has been described as Amryt’s “lead asset”.
Created to treat Epidermolysis Bullosa, a condition where the skin is fragile to the faintest contact, it is currently undergoing phase III clinical trials.
An interim data read-out is expected in the first half of next year. The successful completion of the full study could see AP101 fast-tracked as an orphan drug, which treats an unmet medical need.
The agreement with El Seif covers AP101 in anticipation that the treatment will successfully pass through the clinic.
“We are delighted to be working with El Seif and to have signed this exclusive distribution agreement which covers Lojuxta and AP101,” said chief executive Joe Wiley.
“El Seif has an extensive footprint in Saudi Arabia, and significant breadth and depth of experience and relationships across the institutional and Ministry of Health sectors.
"The signing of this partnership with El Seif is another key milestone for Amryt as we broaden our capability and reach to ensure complete coverage across our key territories."